financetom
Business
financetom
/
Business
/
Stellantis extends employee discount to public as tariffs drive car sales
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis extends employee discount to public as tariffs drive car sales
Apr 4, 2025 8:18 AM

April 4 (Reuters) - Chrysler-parent Stellantis ( STLA )

is extending its employee-discount program to the

wider market on some new models, the company confirmed Friday.

The automaker is giving shoppers the option of taking the

employee incentive pricing, which slashes thousands of dollars

off the vehicle, or accept current retail incentives.

"This week we launched aggressive and consistent

incentive and marketing support for April, including an exciting

and competitive enhancement that will allow our customers

'America's Freedom of Choice' between employee price or current

cash incentives," a Stellantis ( STLA ) spokesperson said in a statement.

The campaign follows a similar move from Ford Motor ( F )

that Reuters

first reported

Wednesday.

U.S. President Donald Trump's 25% tariffs on automotive

imports, and a 10% baseline tariff on all imports, have sent car

companies scrambling.

This week, General Motors ( GM ) said it would

add production

jobs in the U.S., while Stellantis ( STLA ) on Thursday announced it

would temporarily

lay off 900 workers

at five U.S. facilities. The Jeep-maker is pausing

production at some Canadian and Mexican assembly plants, causing

the layoffs at U.S. plants that supply those other North

American facilities. Nissan Motor said

on Thursday

it will not take new orders from the U.S. for two

Mexican-built Infiniti SUVs.

The Stellantis ( STLA ) program covers 2024 model year vehicles

including popular Jeep, Ram and Dodge models, according to a

memo viewed by Reuters. The automaker said the program begins

Friday and runs through April 30.

The Wall Street Journal earlier reported news of the

program.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved